Stramsen Biotech Announces Partnership with Nasdaq Private Market (NPM)
Nyenta.com/10306167

Trending...
HOUSTON, March 11, 2025 ~ Stramsen Biotech Inc. has recently announced a strategic partnership with Nasdaq Private Market (NPM), a specialized division of the renowned Nasdaq exchange, in an effort to enhance their investor relations and capital management capabilities. This New York-based broker-dealer is known for its expertise in facilitating transactions in both private primary and secondary markets, providing unparalleled opportunities for the sale of company and shareholders' shares.

The partnership between Stramsen Biotech Inc. and NPM not only streamlines the company's ability to connect with potential investors but also empowers them to manage their capital structure with unprecedented efficiency. This move is seen as a significant step towards expanding their reach and attracting a diverse range of investors, including individuals, hedge funds, venture capitalists, and institutional investors.

As Stramsen Biotech Inc. approaches the final stages of its Regulation A offering approval process, they are currently raising funds through a Regulation D offering. To ensure a seamless and professional investment experience for their investors, they have partnered with NPM, a prestigious broker-dealer that will facilitate capital raising for both their Regulation A and Regulation D offerings.

More on Nyenta.com
Investors can take advantage of a one-time discount of approximately 86% for Reg A, bringing the current share price down to $1.20 per share. This means that private assets will increase by about 623% based on a single investment purchase for Reg A. Similarly, there is also a one-time discount of approximately 91% for Reg D, bringing the current share price down to $0.80 per share. Investors' private assets will increase by about 983% based on a single purchase of shares for Reg D.

With Stramsen currently valued at $6.5 billion and the current price per share at $8.67, private asset increases are based on a single purchase of Stramsen Biotech shares.

Stramsen Biotech Inc., a biopharmaceutical company, is focused on developing innovative medicines for infectious and non-infectious diseases. With the global pharmaceutical market projected to reach $2.4 trillion by 2029, Stramsen aims to capture 1-5% of this market within 5-15 years. This would result in expected annual gross revenue between $10 billion and $85 billion in the next decade.

More on Nyenta.com
In a show of their commitment to social responsibility, Stramsen Biotech Inc. has announced that they will donate a total of 100,000 shares of the company's common stock to eligible non-profit organizations. These organizations work with disabled military veterans in the US, children living in poverty in developing countries, or refugee camps overseas, as well as select individual veterans.

For more information about Stramsen Biotech Inc. and their partnership with Nasdaq Private Market, please visit their website at www.StramsenBiotech.com or follow them on social media at https://www.facebook.com/StramsenBiotech and https://twitter.com/stramsen.

Contact:

Scott Villwock

President & CEO

7139551156
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on Nyenta.com